All In Biotech

Free tool

FAERS Monitor: Soltamox

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021807 or its brand name (Soltamox, Tamoxifen Citrate). Reports on generic versions are filed under their own applications.

Reports

5,782

Serious

4,458

77% of reports

Hospitalization

1,594

Death reported

477

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue399
  • nausea353
  • diarrhoea283
  • malignant neoplasm progression282
  • arthralgia280
  • pain248
  • vomiting229
  • dyspnoea227
  • breast cancer223
  • dizziness215
  • headache207
  • hot flush199
  • drug ineffective198
  • disease progression192
  • asthenia184

Reports by year received

View as table
YearReports
2004271
2005237
2006487
2007455
2008280
2009485
2010355
2011419
2012399
201360
201462
2015110
2016125
2017150
2018223
2019220
2020213
2021271
2022243
2023219
2024158
2025187
2026153

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,377 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
malignant neoplasm progressionSignal28210.09.02,292
hot flushSignal1999.68.41,531
breast cancerSignal2238.77.71,520
disease progressionSignal1925.95.1782
arthralgiaSignal2802.52.2244
fatigue3991.91.7165
asthenia1841.81.563
vomiting2291.81.678
nausea3531.61.587
diarrhoea2831.61.464
dizziness2151.61.445
pain2481.51.338
dyspnoea2271.51.333
headache2071.21.17
drug ineffective1980.50.579

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.